![conference banner](/images/conference-banner.jpeg)
Abstract
Epigenetics is defined as the stable and heritable alternations in gene expression without changing the DNA nucleotide sequence. The initiation and progression of cancer result from not only genetic mutation, but also aberrant epigenetic regulation, such as DNA methylation and histones acetylation. Although Genetic alternations cannot be reversed, epigenetic modification is a dynamic and reversible process. Over the past few decades, much progress has been made in the research of epigenetic medications and a variety of drugs have been developed targeting at epigenetic regulatory proteins, which are capable of restoring malignant cancer cells to the normal state. The epigenetic drugs currently approved for cancer treatment mainly target at DNA methylation and histones acetylation. In addition, there are a great many epigenetic drugs in clinical trials for cancer therapy, such as inhibitors of DNA methyltransferases, histone deacetylases, histone methyltransferases, lysine specific demethylases, and BET (bromodomain and extra-terminal domain) family proteins. We will discuss the latest developments of these inhibitors and their applications in cancer therapy.
Keywords: Epigenetics drugs, Cancer, Inhibitors, DNA methylation, Histones acetylation, Histone methylation, Epigenetic readers.
Current Topics in Medicinal Chemistry
Title:Epigenetic Targets and their Inhibitors in Cancer Therapy
Volume: 18 Issue: 28
Author(s): Le Zhao, Yong-Tao Duan, Ping Lu, Zhi-Juan Zhang, Xiao-Ke Zheng, Jun-Lei Wang*Wei-Sheng Feng*
Affiliation:
- School of Chemical Engineering and Energy, Zhengzhou University, Zhengzhou,China
- College of pharmacy, Henan University of Chinese Medicine, Zhengzhou,China
Keywords: Epigenetics drugs, Cancer, Inhibitors, DNA methylation, Histones acetylation, Histone methylation, Epigenetic readers.
Abstract: Epigenetics is defined as the stable and heritable alternations in gene expression without changing the DNA nucleotide sequence. The initiation and progression of cancer result from not only genetic mutation, but also aberrant epigenetic regulation, such as DNA methylation and histones acetylation. Although Genetic alternations cannot be reversed, epigenetic modification is a dynamic and reversible process. Over the past few decades, much progress has been made in the research of epigenetic medications and a variety of drugs have been developed targeting at epigenetic regulatory proteins, which are capable of restoring malignant cancer cells to the normal state. The epigenetic drugs currently approved for cancer treatment mainly target at DNA methylation and histones acetylation. In addition, there are a great many epigenetic drugs in clinical trials for cancer therapy, such as inhibitors of DNA methyltransferases, histone deacetylases, histone methyltransferases, lysine specific demethylases, and BET (bromodomain and extra-terminal domain) family proteins. We will discuss the latest developments of these inhibitors and their applications in cancer therapy.
Export Options
About this article
Cite this article as:
Zhao Le , Duan Yong-Tao , Lu Ping, Zhang Zhi-Juan , Zheng Xiao-Ke , Wang Jun-Lei *, Feng Wei-Sheng *, Epigenetic Targets and their Inhibitors in Cancer Therapy, Current Topics in Medicinal Chemistry 2018; 18 (28) . https://dx.doi.org/10.2174/1568026619666181224095449
DOI https://dx.doi.org/10.2174/1568026619666181224095449 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of MALDI/SELDI Mass Spectrometry to Cancer Biomarker Discovery and Validation
Current Proteomics CycloSal-dRFIB, a Thymidine Mimetic, Thymidine Kinase by-Pass Nucleoside Prodrug: Radioiodination, in vitro Cellular Uptake and Biodistribution in Murine Models
Current Radiopharmaceuticals The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets Hypertension in the Elderly: An Evidence-based Review
Current Pharmaceutical Design Angiogenesis and Pancreatic Cancer: Novel Approaches to Overcome Treatment Resistance
Current Cancer Drug Targets Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets
Current Drug Targets Application of Chiral α-Monofluorocarbonyl Compounds to Analytical and Medicinal Chemistry
Current Organic Chemistry Drug-Metabolizing Enzymes Mechanisms and Functions
Current Drug Metabolism Histone Deacetylase Inhibition: A Differentiation Therapy for Cultured Primary Hepatocytes?
Current Enzyme Inhibition Natural Products as a Promising Therapeutic Strategy to Target Cancer Stem Cells
Current Medicinal Chemistry Role of PGE2 in Blood Pressure Regulation
Current Hypertension Reviews STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Current Medicinal Chemistry Laminin and Collagen IV: Two Polypeptides as Marker of Dystocic Labor
Current Protein & Peptide Science A proteomics based approach for the identification of gastric cancer related markers
Current Pharmaceutical Design Human Sirtuins: An Overview of an Emerging Drug Target in Age-Related Diseases and Cancer
Current Drug Targets New Analytical Tools for Studying Autoimmune Diseases
Current Pharmaceutical Design Development and Validation of a Prognostic Model based on 11 E3-related Genes for Colon Cancer Patients
Current Pharmaceutical Design MIF and CD74 - Suitability as Clinical Biomarkers
Mini-Reviews in Medicinal Chemistry Current Status of Imaging Infections with Radiolabeled Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry Intrathecal Administration of Melatonin Ameliorates the Neuroinflammation- Mediated Sensory and Motor Dysfunction in A Rat Model of Compression Spinal Cord Injury
Current Molecular Pharmacology